Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades.

The field of molecular and biochemistry diagnostics of adrenal tumors is rapidly evolving, driven by the need to accurately diagnose and manage these complex conditions. Adrenal incidentalomas, which ...